Overview
- Reuters reports Ozempic will be available in India this month as Novo Nordisk partners with Healthify on coaching-based patient support, and a Delhi court blocked Sun Pharma from selling a semaglutide formulation until Novo’s patent expires.
- Novo Nordisk submitted an sNDA for a 7.2 mg semaglutide dose for chronic weight management, with management indicating an expedited FDA review could follow within one to two months after filing acceptance.
- Argus downgraded the shares to Hold on December 8, citing GLP-1 market-share losses, U.S. pricing concessions, and the prospect of generic competition in some markets.
- Roughly 60% of covering analysts rate the stock a Buy, with a median price target near $62, according to recent summaries that include Berenberg’s view.
- Shares are down about 48% year to date as confidence is tested by mixed clinical updates, including a semaglutide Alzheimer’s study that did not show slowed disease progression.